{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-014972","form_type":"8-K","ticker":"ZBH","cik":"0001136869","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.017122+00:00","generated_at":"2026-05-27T01:25:36.997180+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Zimmer Biomet Q4 sales $2.02B (+4.9% CC), adj. EPS $2.31; guides FY2025 adj. EPS $8.15-$8.35","bullets":["Q4 net sales $2.023B (+4.9% constant currency); Q4 adjusted diluted EPS $2.31.","Full-year net sales $7.679B (+4.8% CC); full-year adjusted diluted EPS $8.00.","FY2025 guidance: constant currency revenue growth 3%-5%; adjusted diluted EPS $8.15-$8.35.","Announced definitive agreement to acquire Paragon 28 (FNA) for foot & ankle segment; terms not disclosed.","Received FDA PMA for Oxford Cementless Partial Knee and FDA 510(k) for OsseoFit Stemless Shoulder."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-014972","json":"https://secwatch.observer/filing/0000950170-25-014972.json","markdown":"https://secwatch.observer/filing/0000950170-25-014972.md","text":"https://secwatch.observer/filing/0000950170-25-014972.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1136869/000095017025014972/0000950170-25-014972-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1136869/000095017025014972/zbh-20250206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:25:36.997180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}